Heidelberg Pharma AG, a clinical-stage company developing innovative Antibody Drug Conjugates (ADCs), announced it will present new data from its Phase I/IIa clinical study with its lead Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), in an oral presentation, as well as data from its second clinical candidate, HDP-102, during the poster abstract session of the 68th Annual Meeting of the American Society of Hematology (ASH), being held in New Orleans, USA, from 12 to 15 December 2026. The announcement, reported via NEWMEDIAWIRE, signals important clinical progress for the company's novel ATAC technology platform.
The oral presentation will feature data from the first-in-human phase 1/2a study of pamlectabart tismanitin, an anti-BCMA antibody-Amanitin drug conjugate for the treatment of relapsed or refractory multiple myeloma (RRMM), a bone marrow cancer with a high unmet medical need. The presentation, titled "First-in-human phase 1/2a study of pamlectabart tismanitin (HDP-101), an amanitin-based BCMA-targeting antibody-drug conjugate (ADC): Recommended phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed/refractory multiple myeloma (RRMM)," will be given by Professor Marc-Steffen Raab, MD, on Saturday, 12 December 2026. The Phase I dose-escalation part of the study included ten patient cohorts, was completed in April 2026, and determined the recommended dose for the Phase IIa expansion part. Pamlectabart tismanitin demonstrated consistent clinical activity with a favorable safety profile in heavily pretreated RRMM patients, supporting its potential as a novel payload BCMA-targeted ADC therapy. The abstract is available in the ASH® ANNUAL PROGRAM.
The poster presentation will detail HDP-102, a first-in-class CD37-targeted amanitin-based ADC, demonstrating translational activity and favorable early safety and efficacy in relapsed/refractory B-cell malignancies. Dr. Irina Mocanu, MD, will present the data on Sunday, 13 December 2026. HDP-102 targets CD37, which is overexpressed on B-cell lymphoma cells, and preclinical studies have shown excellent anti-tumor efficacy and good tolerability. In 2025, Heidelberg Pharma announced the dosing of the first patient with HDP-102. Three patients were treated with 40 µg/kg in the first cohort, with the treatment well tolerated and initial signs of biological activity observed at the very low dose. Two patients showed stabilization of the disease with regression and reduction of lymph nodes. The safety committee recommended increasing the dose to 65 µg/kg in cohort 2. However, in line with Heidelberg Pharma's strategic decision from September 2025 to discontinue the study, the company is exploring partnership opportunities to support the continuation of the program. The abstract is available in the ASH® ANNUAL PROGRAM.
The presentations at ASH 2026 are significant because they provide the first clinical data for Heidelberg Pharma's ATAC candidates in multiple myeloma and B-cell malignancies, potentially validating the company's Amanitin-based ADC technology. For investors and partners, the data could influence the future development and partnering prospects of these programs. Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom, and its ATAC technology represents a new therapeutic modality. More information about the company is available at http://www.heidelberg-pharma.com/.
